Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
To learn if sacituzumab govitecan can help to control salivary gland cancer.
Patients ≥18 years with histology-proven R/M salivary gland cancer. [+15]
Prior radiation therapy (or other non-systemic therapy) within 2 weeks prior to... [+17]